Royalty Pharma PLC Form 4 insider transactions

Royalty Pharma's EVP & CFO, Terrance P. Coyne, acquired 26,626 Class A Ordinary Shares through the settlement of equity performance awards.

Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, reported the future acquisition of 26,626 Class A Ordinary Shares through equity performance awards and a disposition of 70,000 shares, effective February 11, 2026.

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, reported the sale of 243,541 Class A Ordinary Shares through a pre-arranged 10b5-1 trading plan.

Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 20,000 Class A Ordinary Shares for over $41 per share as part of a pre-arranged trading plan.

Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold 20,000 Class A Ordinary Shares for approximately $40.26 per share under a pre-arranged 10b5-1 plan.

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, sold 69,582 Class A Ordinary Shares for approximately $39.35 per share under a pre-arranged 10b5-1 plan.

Royalty Pharma plc's EVP of Research & Investments, Marshall Urist, sold 20,000 Class A Ordinary Shares for approximately $39.52 per share as part of a pre-arranged trading plan.

Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold 20,000 Class A Ordinary Shares for $40.78 per share as part of a pre-arranged 10b5-1 trading plan.

Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 69,582 Class A Ordinary Shares for approximately $38.42 per share under a pre-arranged 10b5-1 plan.

Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold 20,000 Class A Ordinary Shares for $38.4825 per share under a pre-arranged 10b5-1 plan.

Royalty Pharma plc Director Bonnie L. Bassler acquired 967 Class A Ordinary Shares as part of her compensation plan.

Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold 20,000 Class A Ordinary Shares for approximately $39.32 per share under a pre-arranged 10b5-1 plan.

Royalty Pharma's EVP of Research & Investments, Marshall Urist, has filed a Form 4 disclosing a planned sale of 20,000 Class A Ordinary Shares on December 19, 2025, under a Rule 10b5-1 plan.

Royalty Pharma's EVP of Investments & CLO, George W. Lloyd, sold 110,000 Class A Ordinary Shares in pre-planned transactions totaling approximately $4.24 million.

Royalty Pharma's EVP of Research & Investments, Marshall Urist, reported the sale of 20,000 Class A Ordinary Shares under a pre-arranged trading plan.

Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 69,582 Class A Ordinary Shares for approximately $38.36 per share under a pre-arranged 10b5-1 plan.

Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold over 41,000 Class A Ordinary Shares for approximately $39.15 per share under a pre-arranged 10b5-1 plan.

Royalty Pharma's EVP of Investments & CLO, George W. Lloyd, sold 110,000 Class A Ordinary Shares for approximately $39.77 per share as part of a pre-arranged 10b5-1 trading plan.

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, sold 69,582 Class A Ordinary Shares for approximately $2.77 million under a pre-arranged 10b5-1 trading plan.

Royalty Pharma's EVP of Research & Investments, Marshall Urist, sold over 41,000 Class A Ordinary Shares in pre-arranged transactions.

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.68 million under a pre-arranged 10b5-1 trading plan on November 24, 2025.

Royalty Pharma's EVP of Investments & CLO, George W. Lloyd, sold 135,426 Class A Ordinary Shares for approximately $5.19 million under a pre-arranged 10b5-1 plan.

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, sold 69,594 Class A Ordinary Shares for approximately $39.30 per share under a pre-arranged 10b5-1 plan.

Royalty Pharma plc's CEO and Chairman, Pablo G. Legorreta, acquired 36,559 Class A Ordinary Shares through the settlement of equity performance awards.

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, acquired 6,168 Class A Ordinary Shares through the settlement of equity performance awards.

Royalty Pharma's EVP of Investments & CLO, George W. Lloyd, acquired 6,168 Class A Ordinary Shares through an equity award settlement.

Royalty Pharma plc's EVP & Vice Chairman, Christopher Hite, reported the acquisition of 6,168 Class A Ordinary Shares and the disposal of 70,000 Class A Ordinary Shares.

Royalty Pharma plc's EVP of Research & Investments, Marshall Urist, reported the acquisition of Class A Ordinary Shares from equity awards and an exchange of limited partnership interests for Class A Ordinary Shares.

Royalty Pharma plc Director Bonnie L. Bassler acquired 1,047 Class A Ordinary Shares as part of her compensation plan.

A director at Royalty Pharma plc converted partnership interests into Class A Ordinary Shares and subsequently sold a portion of those shares.